ConvaTec Group PLC
LSE:CTEC

Watchlist Manager
ConvaTec Group PLC Logo
ConvaTec Group PLC
LSE:CTEC
Watchlist
Price: 235.8 GBX 2.25% Market Closed
Market Cap: 4.8B GBX
Have any thoughts about
ConvaTec Group PLC?
Write Note

ConvaTec Group PLC
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ConvaTec Group PLC
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ConvaTec Group PLC
LSE:CTEC
Cost of Revenue
-$920m
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Abingdon Health PLC
LSE:ABDX
Cost of Revenue
-ÂŁ2m
CAGR 3-Years
-35%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Tristel PLC
LSE:TSTL
Cost of Revenue
-ÂŁ6.9m
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Inspecs Group PLC
LSE:SPEC
Cost of Revenue
-ÂŁ99.7m
CAGR 3-Years
-55%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Advanced Medical Solutions Group PLC
LSE:AMS
Cost of Revenue
-ÂŁ59.7m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
Cambridge Nutritional Sciences PLC
LSE:CNSL
Cost of Revenue
-ÂŁ3.7m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ConvaTec Group PLC
Glance View

Market Cap
4.8B GBX
Industry
Health Care

ConvaTec Group PLC is a global medical technology company that specializes in the development and marketing of advanced products for wound care, ostomy care, continence care, and critical care. Founded in 1978 and headquartered in the UK, ConvaTec has established itself as a leader in the healthcare space, relentlessly focusing on innovative solutions that enhance patient outcomes and streamline healthcare delivery. With a diverse portfolio of trusted brands such as AQUACEL® and Versiva®, the company provides essential products that cater to the needs of patients with chronic, acute, and complex wounds as well as those requiring ostomy care. The company's growth trajectory has been bolstered by strategic investments in research and development, positioning it as a pioneer in integrating cutting-edge technologies into its offerings. As an investor, ConvaTec presents a compelling opportunity driven by increasing demand in the healthcare sector, notably due to an aging population, rising prevalence of chronic conditions, and heightened awareness of infection control. The company has demonstrated resilience and adaptability in navigating market fluctuations, evidenced by its strong revenue growth and operational improvements. With a robust pipeline of innovative products and a commitment to sustainability, ConvaTec is well-positioned to capitalize on emerging trends in healthcare. As healthcare evolves, its focus on delivering high-quality solutions not only enhances patient experiences but also promises to yield solid returns for investors looking to support the future of medical innovation.

CTEC Intrinsic Value
278.46 GBX
Undervaluation 15%
Intrinsic Value
Price

See Also

What is ConvaTec Group PLC's Cost of Revenue?
Cost of Revenue
-920m USD

Based on the financial report for Dec 31, 2023, ConvaTec Group PLC's Cost of Revenue amounts to -920m USD.

What is ConvaTec Group PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-2%

Over the last year, the Cost of Revenue growth was 3%. The average annual Cost of Revenue growth rates for ConvaTec Group PLC have been -2% over the past three years , -2% over the past five years .

Back to Top